Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:JNCE

Jounce Therapeutics (JNCE) Stock Price, News & Analysis

Jounce Therapeutics logo

About Jounce Therapeutics Stock (NASDAQ:JNCE)

Advanced Chart

Key Stats

Today's Range
$1.88
$1.88
50-Day Range
$1.84
$1.94
52-Week Range
$0.58
$5.87
Volume
169,314 shs
Average Volume
2.46 million shs
Market Capitalization
$98.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive JNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jounce Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JNCE Stock News Headlines

“The Best Gold Investment You’ve Never Heard Of”
Gold may be surging past $3,500 — but one rare class of stocks is leaving bullion in the dust. Gold royalties have outpaced physical gold by 150X and even outperformed Buffett’s track record by 18,200%. These companies don’t mine gold… they get paid in gold. Now, one analyst is revealing his top 3 picks.
See More Headlines

JNCE Stock Analysis - Frequently Asked Questions

Jounce Therapeutics, Inc. (NASDAQ:JNCE) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.15.

Jounce Therapeutics (JNCE) raised $76 million in an initial public offering on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Jounce Therapeutics investors own include CRISPR Therapeutics (CRSP), Exelixis (EXEL), Meta Platforms (META), Sorrento Therapeutics (SRNE), Johnson & Johnson (JNJ), Novavax (NVAX) and OPKO Health (OPK).

Company Calendar

Last Earnings
11/04/2021
Today
7/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:JNCE
CIK
1640455
Fax
N/A
Employees
137
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.92 million
Net Margins
N/A
Pretax Margin
-61.93%
Return on Equity
-30.90%
Return on Assets
-26.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.37
Quick Ratio
8.37

Sales & Book Value

Annual Sales
$82 million
Price / Sales
1.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.54 per share
Price / Book
0.53

Miscellaneous

Outstanding Shares
52,630,000
Free Float
48,993,000
Market Cap
$98.94 million
Optionable
Optionable
Beta
0.75

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:JNCE) was last updated on 7/14/2025 by MarketBeat.com Staff
From Our Partners